Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.69 |
| ▸ | CA2 | P00918 | 4/20 | 0.69 |
| ▸ | CA9 | Q16790 | 2/20 | 0.69 |
| ▸ | DHFR | P00374 | 8/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15267667 | 0.88 | CA1 (0.56) | CA1CA2CA9DHFR | |
| SCHEMBL480787 | 0.84 | DHFR (0.67) | CA1CA2CA9DHFR | |
| SCHEMBL13186956 | 0.84 | DHFR (0.67) | CA1CA2CA9DHFR | |
| SCHEMBL11633503 | 0.84 | CA1 (0.70) | CA1CA2CA9DHFR | |
| SCHEMBL21319444 | 0.84 | CA1 (0.70) | CA1CA2CA9DHFR | |
| SCHEMBL11634264 | 0.83 | DHFR (0.76) | CA1CA2CA9DHFR | |
| SCHEMBL13640684 | 0.82 | DHFR (0.65) | CA1CA2CA9DHFR | |
| SCHEMBL11633634 | 0.82 | DHFR (0.78) | CA1CA2CA9DHFR | |
| SCHEMBL14417311 | 0.82 | DHFR (0.81) | CA1CA2CA9DHFR | |
| SCHEMBL11633089 | 0.81 | DHFR (0.69) | CA1CA2CA9DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221372-A1 | VITAMIN RECEPTOR DRUG DELIVERY CONJUGATES FOR TREATING INFLAMMATION | ENDOCYTE INC (US) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221372-A1 | VITAMIN RECEPTOR DRUG DELIVERY CONJUGATES FOR TREATING INFLAMMATION | VDR, HCAR1, CYP2R1 | CA1 4083/4885CA2 3441/4885CA9 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.